656827-86-0 Usage
Uses
Used in Pharmaceutical Industry:
(R)-SLV 319 is used as a chiral reference compound for the development and synthesis of new CB1 receptor antagonists. Its inactive nature allows researchers to study the differences in biological activity between enantiomers and optimize the therapeutic potential of CB1 receptor antagonists.
Used in Research Applications:
(R)-SLV 319 is used as a research tool to investigate the role of CB1 receptors in various diseases and disorders. It helps researchers understand the mechanism of action of CB1 receptor antagonists and their potential therapeutic effects.
Used in Drug Development:
(R)-SLV 319 can be used in the development of new drugs targeting the CB1 receptor, as it provides insights into the structure-activity relationship of CB1 receptor antagonists. This information can be valuable in designing more potent and selective CB1 receptor antagonists for the treatment of various diseases.
in vitro
(r)-slv 319 is the inactive enantiomer of slv 319 with 100-fold less affinity for the cb1 receptor. slv 319 was identified as a potent and selective cb1 receptor antagonist with ki values of 7.8 and 7,943 nm for cb1 and peripheral cannabinoid (cb2) receptors, respectively. slv 319 was found to be less lipophilic and thus more water soluble than other known cb1 receptor ligands [1,2].
in vivo
a previous animal study examined the chronic effects of slv 319 in hyperinsulinemic zucker rats to determine their chronic effects on insulinemia. results showed that r slv 319 at 10 mg·kg-1·day-1 elicited body weight-independent improvements in insulinemia and glycemia during 10 wk of chronic treatment. moreover, slv 319 treatment caused glucose intolerance in cb1 but not sur1-ko mice [3].
references
[1] lange, j. h.m.,coolen, h.k.a.c.,van stuivenberg, h.h., et al. synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective cb1 cannabinoid receptor antagonists. journal of medicinal chemistry 47(3), 627-643 (2004).[2] lange, j. h.m.,van stuivenberg, h.h.,veerman, w., et al. novel 3,4-diarylpyrazolines as potent cannabinoid cb1 receptor antagonists with lower lipophilicity. bioorganic & medicinal chemistry letters 15, 4794-4798 (2005).[3] lynch cj, zhou q, shyng sl, heal dj, cheetham sc, dickinson k, gregory p, firnges m, nordheim u, goshorn s, reiche d, turski l, antel j. some cannabinoid receptor ligands and their distomers are direct-acting openers of sur1 k(atp) channels. am j physiol endocrinol metab. 2012 mar 1;302(5):e540-51.
Check Digit Verification of cas no
The CAS Registry Mumber 656827-86-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,5,6,8,2 and 7 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 656827-86:
(8*6)+(7*5)+(6*6)+(5*8)+(4*2)+(3*7)+(2*8)+(1*6)=210
210 % 10 = 0
So 656827-86-0 is a valid CAS Registry Number.
